Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider

The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.

07/24/2026, 9:30 AM • GlobeNewswire

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

Grifols announced the initiation of two Phase 3 clinical trials (SIGMA and XPERT) to expand U.S. label indications for its immunoglobulin therapies GAMUNEX-C and XEMBIFY. The SIGMA trial will evaluate GAMUNEX-C in secondary immunodeficiency patients with blood cancers, while XPERT will assess XEMBIFY's non-inferiority to GAMUNEX-C in CIDP patients. These trials aim to provide patients with more treatment options and support potential regulatory label expansions.

07/16/2026, 8:00 AM • GlobeNewswire

Global Human Fibrinogen Concentrate Market Size/Share Worth USD 2.78 Billion by 2035 at a 11.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global human fibrinogen concentrate market, valued at USD 0.95 billion in 2025, is projected to grow at a 11.3% CAGR to reach USD 2.78 billion by 2035. Growth is driven by increasing bleeding disorders, surgical procedures, and demand for effective hemostatic therapies. Lyophilized forms dominate the market, with hospitals being the primary end-users. Asia Pacific is expected to experience the highest growth rate.

07/01/2026, 12:30 AM • GlobeNewswire

Health Coalition demands disclosures & end to Grifols’ for-profit blood plasma contract following reports of deaths, harm, non-compliance

Health coalitions in Ontario and Manitoba are calling for the end of Canadian Blood Services' contract with pharmaceutical corporation Grifols following reports of patient deaths, kidney damage, and multiple non-compliance findings at for-profit plasma collection centres across Canada. The coalitions are demanding full disclosure of contract terms, compliance reports, and adverse events, and are calling for expansion of the voluntary public blood donation system instead of for-profit plasma harvesting.

03/13/2026, 4:41 PM • GlobeNewswire

Blood Group Typing Global Market Overview 2025-2030: PCR-based Techniques Command the Largest Share

Global blood group typing market expected to grow from $2.4 billion in 2024 to $3.9 billion by 2030, driven by advancements in molecular technologies, increasing surgeries, and healthcare infrastructure expansion in emerging economies.

11/14/2025, 6:47 AM • GlobeNewswire

Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035

The global CIDP market is growing due to increased awareness, improved diagnostics, and demand for advanced treatments, with key players driving innovation in targeted biologic therapies despite challenges like high treatment costs and limited options for refractory cases.

08/11/2025, 5:48 AM • GlobeNewswire

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst Pharmaceuticals announced that Charlie Gayer will succeed Jon Stonehouse as CEO, effective January 1, 2026, after a successful commercial launch of ORLADEYO and driving significant revenue growth.

07/31/2025, 7:00 AM • GlobeNewswire